ArticleEJNMMI research2025
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fibroblast activation protein-targeted molecular imaging in interstitial lung disease: a systematic review.Annals of nuclear medicine · 2026Pooled it
- Article
- Fibroblast activation protein inhibitor (FAPI) PET imaging in pulmonary fibrosis: pathophysiology, clinical utility, and emerging theranostic applications.Respiratory research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe pathogenesis of connective tissue disease-associated interstitial lung disease (CTD-ILD) involves complex interactions between inflammatory cell infiltration and fibroblast activation, which are pivotal in driving the disease progression. The aim of the study was to assess the feasibility of 99mTc-HFAPI imaging for visualizing active fibrotic process and 18F-FDG imaging for visualizing inflammatory process in CTD-ILD patients.
resultsA total of 54 CTD-ILD patients were enrolled. Visual analysis revealed that nearly half of the patients exhibited high tracer uptake on 99mTc-HFAPI imaging, whereas most patients showed low or moderate uptake on 18F-FDG imaging. 8 patients showed high uptake in both scans. 15 patients showed low or moderate 18F-FDG uptake but high 99mTc-HFAPI uptake. No patients demonstrated high 18F-FDG uptake coupled with low 99mTc-HFAPI uptake were observed among these 54 patients. Correlation analysis between 99mTc-HFAPI parameters and pulmonary function testing (PFT) results showed 99mTc-HFAPI uptake was significantly negatively correlated with forced vital capacity (FVC) [whole lung (wl) SUVmean: R=-0.45, p < 0.005; metabolic active volume (MAV): R=-0.41, p < 0.005; total lesion (TL): R=-0.45, p < 0.005] and diffusion capacity for carbon monoxide (DLCO) (wlSUVmean: R=-0.58, p < 0.005; MAV: R=-0.62, p < 0.005; TL: R=-0.65, p < 0.005). Significantly positive correlations were observed between 99mTc-HFAPI parameters and disease extent on HRCT (wlSUVmean: R = 0.51, p < 0.005; MAV: R = 0.53, p < 0.005; TL: R = 0.64, p < 0.005). In contrast, 18F-FDG parameters demonstrated weak or mild correlations with both PFT results and disease extent on HRCT.
conclusion99mTc-HFAPI imaging shows promising utility in assessing active fibrosis in CTD-ILD patients, demonstrating superior performance over 18F-FDG. The potential added value of dual-tracer imaging for characterization fibrotic and inflammatory processes might provide more insights of CTD-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.